MedTrace Logo

HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir

NCT01222611 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2014-05-30

No results posted yet for this study

Summary

This study examines the impact of fosamprenavir as part of an ART on virological, immunological and clinical parameters of genotype 1 HCV infection in HIV co-infected subjects. Fosamprenavir could have a direct or immune-mediated activity against HCV. If this is shown to be true, changes in HCV viral load or biological characteristics could be demonstrated.

Conditions

  • Chronic HIV Infection
  • HCV Coinfection

Interventions

DRUG

Fosamprenavir

HAART including fosamprenavir boosted with ritonavir

Sponsors & Collaborators

  • ViiV Healthcare

    collaborator INDUSTRY

  • Fundacion SEIMC-GESIDA

    lead OTHER

Principal Investigators

  • Juan Gonzalez, MD · Hospital La Paz, Madrid (Spain)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01222611 on ClinicalTrials.gov